In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
BIOMED X LAUNCHES NEW US INSTITUTE IN NEW HAVEN, CT
Yale Ventures
Yale Ventures Managing Director Josh Geballe took part in the opening ceremony on Tuesday and expressed his excitement for the collaboration potential that BioMed X brings to New Haven: “Yale is committed to global partnerships that foster innovation. We warmly welcome BioMed X to our bio-ecosystem and are looking forward to future collaborations.”
BioMed X Launches New US Institute in New Haven, CT
Yahoo! Finance
Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
PharmiWeb
The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
MarketWatch
The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
FinanzNachrichten
German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
Yahoo! Finance
The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.
BioMed X and AbbVie Extend Research Collaboration in the US
Street Insider
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
The BioMed X Institute: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
FinanzNachrichten
“We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases,” said Carine Boustany, PhD, Global Head of Immunology & Respiratory Diseases Research, Boehringer Ingelheim.
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Yahoo! Finance
XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration with Boehringer Ingelheim
PharmiWeb
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
WebDisclosure
BioMed X Institute’s new XSeed Labs research team starts activity in the U.S. in collaboration with Boehringer Ingelheim.
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
BioSpace
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
New Immuno-Oncology Research Project in Partnership With Merck KGaA Starts at the BioMed X Institute in Heidelberg
FinanzNachrichten
Dr. Semih Akincilar, the scientist leading this project, explains: “Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment.”
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Yahoo! Finance
“With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology,” said Christian Tidona, Founder and Managing Director of the BioMed X Institute.
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
BioSpace
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.
Israeli startup to use AI to transform antibody discovery, design
Israel’s AION Labs announced last week the launch of CombinAble.AI, a startup focused on improving antibody design to speed up the development of better therapeutics.
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
Yahoo! Finance
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
PR Newswire
New Startup Formed by Israel-Based Venture Studio Leverages AI to Accelerate Discovery Process for More Effective Biological Therapeutics for a Range of Diseases
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
PharmiWeb
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Healthcare Industry Baden WĂĽrttemberg (powered by BioPro)
BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON). The main objective of…
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Yahoo! Finance
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.